National OncoVenture
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://nov.ncc.re.kr
NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- National OncoVenture
- Target Recruit Count
- 30
- Registration Number
- NCT02300467
- Locations
- π°π·
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
Phase 2
Terminated
- Conditions
- Adenocarcinoma of Lung Stage IVAdenocarcinoma of Lung Stage IIIB
- Interventions
- Drug: NOV120101 (Poziotinib)
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- National OncoVenture
- Target Recruit Count
- 22
- Registration Number
- NCT01819428
- Locations
- π°π·
Ulsan University Hospital, Dong-gu, Ulsan, Korea, Republic of
π°π·Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of
π°π·Gachon University Gil Hospital, Namdong-Gu, Incheon,, Korea, Republic of
NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
Phase 2
Completed
- Conditions
- Increased Drug Resistance
- Interventions
- Drug: NOV120101 (Poziotinib)
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- National OncoVenture
- Target Recruit Count
- 40
- Registration Number
- NCT01718847
- Locations
- π°π·
Gachon University Gil Medical Center, Incheon, Korea, Republic of
π°π·Ulsan University Hospital, Dong-gu, Ulsan, Korea, Republic of
π°π·Chungbuk National University Hospital, Cheongju-si,, Chungcheongbuk-do, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath